Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2001

View Archived Issues

Pivotal trials of Sepracor's rapid- and long-acting bronchodilator initiated

Sibutramine metabolite in phase II for sexual dysfunction

Sepracor initiates clinical testing of new compound for anxiety

Forest seeks FDA approval for new calcium channel blocker

First target from Lexicon's drug discovery program unveiled

Uriach compound for IBD with unique mechanism of action licensed to Interneuron

Clinical trial in asthmatics demonstrates bronchoprotective effect for sildenafil

Clinical data discussed at ERS meeting support use of omalizumab in allergic asthma, rhinitis

NBI-34060 to move to phase III following positive phase II results

Promising phase II results obtained for BBR-2778 in non-Hodgkin's lymphoma

Study on stability of synthetic red blood cell substitute reported successful

New diagnostic test for mad cow and Creutzfeldt-Jakob disease enters clinical testing

rSP-C-based surfactant effective in acute lung injury when given as therapeutic lavage

CNS excitability reduced by rhubarb extracts in rat hippocampal neurons

ORP150: therapeutic potential in stroke

Good stability, favorable pharmacokinetics determined for LJP-920

Key pharmacokinetic findings, integrated phase III data analysis presented in Rome for Cialis

Pamidronate reduces bone loss in men on prostate cancer treatment

Teijin describes preparation and use of new chymase inhibitors

BMS discloses new series and uses of cannabinoid receptor modulators

Integrin antagonists under early development at Merck KGaA

Antiulcer agents from Sankyo inhibit H+/K+-ATPase and H. pylori

Newly claimed Rho kinase inhibitors with wide range of therapeutic applications

Advanced Medicine discloses new nicotinic acetylcholine receptor modulators and use as analgesics

MTP inhibitors from Advanced Medicine reportedly useful for atherosclerosis

Novel compounds for HCV infection patented by Schering-Plough

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...